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ABSTRACT
PURPOSE: To evaluate the contribution of L-arginine oral or topical rout of administration in the surgical wound healing process.
METHODS: L-arginine was orally or topically administrated to mice after a laparotomy model procedure. The wounds were analyzed 
to evaluate the granulation tissue by HE analysis, collagen deposition, iNOS and cytokines production by immunochemisyry on wound 
progress. Mice used in this model were healthy, immunosupressed or diabetic and all of them were treated with different concentration 
of L-arginine and rout of administration. 
RESULTS: Suggested that groups treated with L-arginine orally or topically improved wound repair when compared with non-treatad 
mice. L- arginine treatment stimulated TGF-β and restricted NO production leading to a mild Th1 response and collagen deposition in 
injured area, when it was orally administrated. Topical administration decreased IL-8 and CCR1 expression by wound cells but did not 
interfere with TNF-α and IL-10 production, ratifying the decrease of inflammatory response, the oral administration however,  presented 
a higher iNOS and TGF-β expression then. L-arginine treatment also improved the improved the wound healing in immunosupressed 
or diabetic mice.
CONCLUSION: L-arginine administrated orally or topically can be considered an important factor in the recuperation of tissues.
Key words: Arginine. Wound Healing. Transforming Growth Factor beta. Nitric Oxide. Cytokines. Mice.
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Introduction
Rapid and efficient tissues repair after trauma-induced 
immunological injury is critical for preventing infections1. 
Wound healing, both after surgery or tissue injury, is mediated by 
many different cell types and it is dependent on the production 
of cytokines and growth factors, as well as adequate nutritional 
support2. The healing process, which occurs after the recruitment 
of innate and adaptive immune cells to the injury site, is composed 
of four stages of tissue repair: hemostasis, inflammation, cell 
proliferation and repair, and tissue remodeling3.
Inflammation, an important healing step that occurs 
between 24 and 72 hours after hemostasis, involves the recruitment 
of inflammatory cells to the injured site, particularly myeloid 
cells that contribute to several phases of the immune response. 
Neutrophils and macrophages, the main myeloid cell types 
involved in inflammation, are regulated by different nutritional 
and cytokine environments. Depending on the stimulus, these 
cells can produce a number of cytokines, such as tumor necrosis 
factor alpha (TNF-α), interleukin 8 (IL-8), interleukin 1 (IL-1) 
and transforming growth factor beta (TGF-β), that participate in 
the activation and chemotaxis of a wide range of cells4. The cell 
activation process can determine the time of inflammation duration 
and the beginning of repair phase.
L-arginine metabolism has been described in the 
activation of myeloid cells. This dibasic amino acid is synthesized 
de novo from proline, glutamine or glutamate5. Advances in 
nutritional therapy have suggested that dietary supplementation 
with L-arginine strengthens the immune system due to the 
participation of L-arginine in protein synthesis, signaling and cell 
proliferation6. However, the effect of L-arginine supplementation 
on the immune system is still unclear, and its therapeutic 
application has been controverse. L-arginine can be catabolized by 
nitric oxide synthase (NOS) or arginase (ARG), producing nitric 
oxide (NO) and L-citrulline or urea and L-ornithine, respectively7. 
In mammals, ARG exists in two different isoforms, type I arginase 
(ARG1), a cytosolic enzyme, and type II arginase (ARG2), a 
mitochondrial enzyme. L-arginine metabolism by ARG promotes 
fibroblast replication and collagen production, which are important 
in the early phases of wound healing8.
Three different NOS isoforms have been described, 
differing in their cellular location, catalytic properties and 
inhibitors. NOS1, also known as nNOS, is prevalent in nervous 
tissue, whereas NOS2 or iNOS, the inducible form, is present in 
a range of immune cells and NOS3, or eNOS, can be found in 
endothelia. NOS isoforms are responsible for the synthesis of NO, 
which is not only a potent microbicidal mediator of the immune 
system but it is also a regulator of immediate epithelialization, 
vascular tone, adhesion molecules expression, leukocyte adhesion, 
platelet aggregation and angiogenesis9,10.  Previous works, in 
animal models or humans, have suggested that NO is an important 
constituent of the inflammatory phase of the healing process7. The 
balance between ARG and NOS has been correlated with myeloid 
cell activation status, and differential L-arginine metabolism seems 
to lead to divergent outcomes. Furthermore, the impact of NO and 
L-Arg on the injury repair process is highly dependent on their 
local concentration and the time point of analysis11. Recently, has 
been demonstrated that L-arginine not only stimulates fibroblast 
proliferation but also inhibit apotosis in these cells, and the authors 
showed that this proliferation and survival of the fibroblasts 
occurs through the activiation of ERK1/2-CREB and PI3K/Akt 
pathway12. Considering the literature data, the aim of this work 
was to evaluate the contribution of L-arginine oral or topical rout 
of administration in the surgical wound healing process.
Methods
All procedures performed on animals were in accordance 
with the Brazilian College of Animal Experimentation regulations 
and were approved by the Ethical Committee of Animal Care of 
the University of Brasilia, DF, Brazil (UnBDOC 62941/2008). 
The healthy animals used in these experiments were 
6- to 8-week old Swiss male mice, weighing between 20 and 25 
g, obtained from the vivarium of the Faculty of Medicine, UnB 
Brasilia. Diabetics and immunosuppressed mice were obtained by 
experimental induction of the pathologic conditions on the healthy 
animals. The animals were kept in individual cages, with food 
and water access ad libitum, at 22ºC ± 1°C and were exposed to 
cycles of 12 hours light/darkness. Each group had five animals that 
were randomly distributed. At specific days describe in legends, 
the animals were euthanized with carbon dioxide (CO2) chamber. 
Blood and wound tissue were obtained by caudal puncture. 
Induction of experimental diabetes
Experimental diabetes was induced by streptozotocin 
(STZ) (Sigma-Aldrich®) intraperitoneal administration, with 
a single dose of 60 mg/kg body weight, after mice were fasted 
overnight13. Briefly, STZ was dissolved in freshly prepared 0.025 
M citrate buffer pH 4.5. Animals presenting glycemic plasmatic 
levels over 200 mg/dL, 7 days after STZ administration were 
considered diabetics. 
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Induction of immunosuppression
Experimental immunosuppression in mice was induced 
by intraperitoneal administration of hydrocortisone (União 
Química Nacional®) by two consecutive days, with a dose of 
25 mg/kg body weight22. Immunosuppression induction was 
evaluated by leucocytes count in mice blood one day after the last 
administration of hydrocortisone in comparison with the counting 
acquired one day before de experimental induction.
Experimental design of Laparotomy
Anesthesia was performed by intramuscular injection 
with xylazine (90 mg/kg body weight) (Ceva®) and ketamine 
(100 mg/kg body weight) (Ceva®) Brielfy, for laparotomy, the 
abdomen was shaved, and the skin was disinfected with a 70% 
ethanol and 10% povidone-iodine solution. Surgical procedures 
were performed under aseptic conditions. A midline 3-cm long 
laparotomy was carried out and immediately sutured using 5-0 
nylon and cylinder needles. After 5 or 10 days after the laparotomy 
(DAL) treatment, mice were randomly selected for euthanasia.
L-arginine treatment
Oral administration
Animals were separated into two groups for these 
experiments: group 1 (GO1): control animals treated orally with 
saline solution 7 days before and 7 DAL; and group 2 (GO2): 
animals treated orally with L-arginine 7 days before and 7 DAL. 
The L-arginine solution (Vetec®), 2 g/kg body weight by day, was 
administered by gavage. The wounds were daily analyzed during 
10 days after the laparotomy.
Topical administration
Healthy animals were separated into five groups for 
these experiments and treated in the abdominal region with 
either glycerol only (GT1, n = 5) or a dispersion of L-arginine 
in glycerol at concentrations of 5% (GT2, n = 5), 10% (GT3, n = 
5), 15% (GT4, n= 5) and 40% (GT5, n = 5). Diabetic mice were 
separated in three groups and the treated glycerol only (GD1, 
n=5) or with L-arginine at 10% (GD2, n=5) or 15% (GD3, n=5). 
Immunosuppressed animals were also separated in three groups 
and treated as described above with glycerol only (GI1, n=5) or 
L-arginine at 10% (GI2, n=5) or 15% (GI3, n=5). Each animal 
received 0.5 g of glycerol or L-arginine dispersion topically every 
day from 7 days before to 5 DAL. After this period, mice were 
randomly selected for euthanasia and wounds were analyzed.
Biochemical parameters
Levels of blood urea nitrogen (BUN), creatinine, alkaline 
phosphatase, pyruvic acid and oxaloacetic glutamic transaminases 
were determined from blood samples of animals from groups 
1 and 2, collected under anesthesia. Samples were analyzed by 
spectrometry assay using the Cobas® analyzer (Roche/Hitachi).  
Wound analysis
Tissue preparation
Fragments (3 x 3 cm) of the abdominal tissue containing 
the scar or normal tissue were removed and fixed in neutral 
buffered formalin for 6 hours, embedded by routine techniques 
in paraffin wax and sectioned to 5-µm thickness. Sections were 
subjected to hematoxylin and eosin (HE) or immunohistochemical 
staining.
Immunohistochemical staining
Tissue sections of 5-µm thickness were collected on 
gelatin-coated glass slides. The samples were immersed in 3 
mM citrate buffer (pH 6.0) for 10 minutes at 120°C for antigen 
retrieval, incubated in 3% bovine serum albumin (BSA) and then 
incubated with antibodies directed against one of the following 
marker: TNF-α (1:75 dilution), iNOS, TGF-β, CCR-1, IL-8, 
and IL-10 (1:100 dilution). All antibodies were from Santa Cruz 
Biotechnology, Inc. The sections were incubated with secondary 
antibodies and streptavidin-biotin complex (DAKO, A/S, Glostrup, 
Denmark) for 20 minutes.  Diaminobenzidine chromogen solution 
was added to the reactions, and a counter-stain was performed 
with Mayer’s hematoxylin. As a negative control, 1% BSA was 
used in place of the primary antibody. Positive controls were also 
prepared according to the manufacturer’s instructions.
Cell counting 
The number of positively-stained cells was determined 
for each antibody using an integration graticule (Carl Zeiss-
4740680000000-Netzmikrometer 12.5x). All cells per ten 
consecutive microscopic high power fields of the operatory wound 
fragments were counted (x100). At this magnification, each field 
(integration graticule) has an area equal to 0.015625 mm2. Results 
were expressed as the mean of positive cells ± standard deviation 
(SD) of n observations per mm2 according to the cell counting 
method described in previous studies15. 
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Statistical analysis
Data were analyzed using the one-way analysis of 
variance (ANOVA) test followed by Bonferroni or Dunnett’s 
multiple comparison tests. All statistical tests were performed 
using the software SPSS 10.0.
Results
Effects of dietary supplementation with L-arginine 
on wound healing. 
L-arginine supplementation was well-tolerated, as 
demonstrated by similar serum levels of urea, creatinine, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT) and 
alkaline phosphatase in both groups of animals, GO1 (control) and 
GO2 (animals orally treated for 10 days with L-arginine at a dosis 
of 2 g/kg body weight/day), as shown in Table 1. These results 
indicate that L-arginine supplementation did not affect renal or 
hepatic activities at the concentration used in the experiments. 
TABLE 1 – Biochemical parameters of GO1 and GO2 
animals’s serum.
GO1 GO2
Urea (mg/dL) 59.00 (± 8.56) 66.00 (± 5.95)
Creatinine (mg/dL) 0.40 (± 0.04) 0.31 (± 0.03)
ALT (U/L) 191.11 (± 74.93) 233.8 (± 91.43)
AST (U/L) 20.22 (± 1.39) 21.60 (± 6.63)
Alkaline phosphatase 
(U/L) 264.22 (± 152.07) 503.77 (± 55.97)
Control animals (GO1), orally treated with saline solution only 7 days before and 
7 days after the laparotomy; GO2- Animals orally treated with L-Arginine (2 g/
kg body weight by day) 7 days before and 7 days after the laparotomy; AST- as-
partate aminotransferase; ALT- alanine aminotransferase. Statistical analyses were 
performed by Dunnett’s test (p>0.05). 
Histopathological analysis of surgical wounds in group 1 
mice presented an intense inflammatory process, without fibrosis 
appearance, and with migration of polymorphonuclear cells 
mainly on fifth day after the laparotomy (Figure 1A). On the tenth 
day after the laparotomy, it was observed a smaller infiltration 
of polymorphonuclear cells, although the healing process was 
incomplete (Figure 1C). Similar results were observed for animals 
supplemented with L-arginine in the pre-operatory phase only 
(data not shown). Animals in GO2, which received L-arginine 
supplementation in both pre- and post-operatory phases, exhibited 
an inflammatory process and polymorphonuclear cell infiltration 
into a smaller extent; the wound areas exhibited features of a 
moderate and diffuse inflammatory process without fibrosis 
and an increase in new vein formation on the fifth day post-
operation (Figure 1B). On the tenth day, the wound was almost 
completely healed (Figure 1D). In addition, collagen fibers were 
more organized and mature in the wounds of animals from group 
2 (Figure 1E), indicating that L-arginine has a positive effect on 
collagen production. Taken together, these data suggest that oral 
arginine treatment accelerates and enhances the healing process.
FIGURE 1 - Photomicrography (x200) of HE-stained wound sections 
from animals in GO1 (A and C) and GO2 (B and D). A and B represent 5 
DAL; C and D represent 10 DAL. Tissues of animals from GO1 (E) and 
GO2 (F) were stained with Masson’s Trichrome (specific for collagen) 5 
DAL and visualized under the microscope (x200). Immunoreactivity of 
iNOS (x200) in lesion areas of tissues from GO1 animals 5 DAL (G) or 
10 DAL (H). Immunoreactivity of TGF-β (x200) in lesion areas of tissues 
from GO2 animals 5 DAL (I) or 10 DAL (J). In GO1, control animals 
were treated orally with saline solution 7 days before and 7 days after the 
laparoscopy; and in GO2, animals were treated orally with L-arginine 7 
days before and 7 days after the laparoscopy. 
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The expression of iNOS and TGF-β, inflammatory 
mediators important for the tissue repair process, were also 
examined. Animals in  GO1 exhibited high expression of iNOS 
on the fifth day after laparotomy compared to expression on the 
10th day or in animals not subjected to laparotomy, as depicted 
in Figures 1H and 2. For animals in GO2, we observed similar 
levels of iNOS expression on the 5th and 10th DAL (Figure 2); these 
iNOS levels were comparable to those in control mice 10 days 
after laparotomy and in normal tissue (iNOS in normal tissue - not 
subjected to laparotomy = 175.4 ± 19.5 cell/mm2; iNOS in group 
1 mice on the 5th  DAL = 441.6 ± 113.5 cell/mm2; iNOS in group1 
mice on the 10th DAL = 217.5 ± 76.1 cell/mm2; iNOS in  GO2 
mice 5 DAL = 233.6 ± 59.7 cell/mm2; iNOS in GO2 mice 10 DAL 
= 201.6 ± 56.0 cell/mm2). The expression of TGF-β in GO1 was 
significantly different among animals analyzed on the 5th and 10th 
DAL; animals analyzed on the 10th DAL showed an increase in 
TGF-β production compared to animals that had not undergone 
the laparotomy, as shown in Figure 2 (TGF-β in normal tissue - 
not subjected to laparotomy = 149.6 ± 9.3 cell/mm2; TGF-β in 
group 1 mice on the 5th DAL = 242.9 ± 64.1 cell/mm2; TGF-β in 
group 1 mice 10 DAL = 294.4 ± 70.1 cell/mm2). In GO2 mice, 
the expression of the cytokine TGF-β was higher on the 5th DAL 
and then decreased on the 10th DAL (TGF-β in GO2 mice 5 DAL 
= 422.4 ± 78.8 cell/mm2; TGF-ß inGO2 mice 10 DAL = 188.8 
± 48.6 cell/mm2) to levels similar to those observed in normal 
animals (Figures 1J and 2). Therefore, oral supplementation with 
L-arginine increased the expression of TGF-β and decreased the 
expression of iNOS in the surgical wounds of GO2 animals on the 
5th day after laparotomy.
FIGURE 2 - Expression of iNOS and TGF-β in wound areas 5 DAL 
or 10 DAL.. The results represent the means  ±  SEM of the number of 
positive cells per mm2 counted in ten different fields. Immunostaining for 
iNOS and TGF- β in wound areas are shown. * indicates the difference 
(p < 0.05) relative to normal skin sections stained with antibodies specific 
for iNOS. # indicates difference (p < 0.05) relative to normal skin stained 
with antibodies specific for TGF-β. Results are representative of two 
independent experiments (n=5). Statistical analyses were performed by 
one-way ANOVA followed by Bonferroni’s multiple comparison test. 
Effect of topical administration of arginine on the 
wound healing process
To evaluate whether the topical administration of 
L-arginine could also enhance the wound healing process, 
healthy animals were treated with glycerol only (GT1) or with 
L-arginine at concentrations of 5% ( GT2), 10% (GT3), 15% 
(GT4) or 40% (GT5). The results are shown in Figure 3. Animals 
topically treated with L-arginine showed significantly enhanced 
healing on the fifth day after the laparotomy. The best results were 
obtained when L-arginine was used at concentrations of 10% 
(Figure 3B and F) and 15% (Figure 3C and G). In animals of the 
groupsGT3 and GT4, there was a decrease in polymorphonuclear 
cell infiltration, a markable neovascularization, inflammation, and 
a more intense disorganized and diffuse deposition of collagen 
fibers, especially in animals in GT3 (Figure 3B and F). In animals 
from the group treated with arginine at 40% concentration it was 
observed an intense inflammation process with predominance of 
polymorphonuclear cells and increased collagen deposition.
FIGURE 3 - Photomicrography (x200) of wound sections from animals 
treated  topically with different concentrations of L-arginine. Sections 
were obtained fromGT1 (A and E), GT3 (B and F), GT4 (C and G) and 
GT5 (D and H) 5 DAL and stained with HE (A-D) or Masson’s Trichrome 
(E-H). In GT1, control animals were treated topically with glycerol; in 
GT3, animals were treated with 10% L-arginine; in GT4, animals were 
treated with 15% L-arginine; and in GT5, animals were treated with 40% 
L-arginine. All animals, except for those in GT1, were treated topically 
with L-arginine 7 days before and 5 days after the laparotomy. 
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The expression of iNOS and TGF-β was measured in 
tissues from animals topically treated with L-arginine (Figures 4 
and 5). The expression of iNOS in wound tissue from GT2 and 
GT3 animals was similar to that observed in GT5 animals (Figures 
4A and 5A), and the expression of iNOS in the wound tissue 
of animals in GT4 and GT5 was higher than the control group 
(Figures 4C and 5A). All groups of animals, except GT1 (control), 
showed increased expression of TGF-β (Figures 4D-F and 5B), 
and animals treated with L-arginine at 10% exhibited the most 
marked up-regulation in TGF-β expression (Figures 4D and 5B).
FIGURE 4 - Immunoreactivity of iNOS or TGF-β in lesion areas of 
animals treated topically with different concentrations of L-arginine. 
Immunohistochemical analysis (x200) are shown for GT3 (A and D), GT4 
(B and E) and GT5 (C and F). Sections were incubated with antibodies 
against iNOS (A-C) or TGF-β (D-F) and stained with an avidin-biotin 
complex. In GT3, animals were treated with 10% L-arginine; in GT4, 
animals were treated with 15% L-arginine; and in GT5, animals were 
treated with 40% L-arginine. All animals were treated topically with 
L-arginine 7 days before and 5 days after the laparotomy.
FIGURE 5 - Expression of iNOS and TGF-β in wound areas. The 
results represent the means ± SEM of the number of positive cells per 
mm2 counted in ten different fields. Immunostaining for iNOS (A) and 
TGF-β (B) in wound areas are shown. *indicates the difference (p<0.05) 
relative  between control group and animal treated whit L-Arginine at 
5%, 10%, 15% and 40%. & indicates the diference (p<0.05) relative 
between animals treated with 5% or 40% of L-Arginine. # indicates the 
diference (p<0.05) relative between animals treated with 10% or 40% 
of L-Arginine. ¢ indicates diference (p<0.05) relative between animals 
15% or 40% of L-Arginine.. All animals (n=5) were treated topically 
with L-arginine or vehicle (glycerol) alone 7 days before and 5 days 
after the laparotomy. The results are representative of two independent 
experiments. Statistical analysis were performed using one-way ANOVA 
test followed by Bonferroni’s multiple comparison test.
Other important proteins in the maintenance the of 
inflammatory process had their expression evaluated in animals 
from GT1, GT3 and GT5, including TNF-α, IL-8, IL-10 and 
CCR-1 (Figure 6). TNF-α expression was higher in wounds 
tissues of animals in GT5, whereas TNF-α expression was similar 
in the wounds tissues of animals in GT1 and GT3 (Figure 6A). 
IL-8 expression was lower in the wounds areas in animals from 
GT3 and it was higher in the wounds areas in animals from GT5 
when compared to control group (Figure 6B). IL-10 expression 
in the wounds tissues of animals in group 7 was significantly 
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higher than in the wounds tissues of animals in GT1 (Figure 6C). 
CCR-1 expression was also down-regulated in the wounds areas 
of animals in GT3 and up-regulated in animals from GT5 when 
compared to control (Figure 6D). 
FIGURE 6 - Expression of TNF-α, IL-8, IL-10 and CCR1 in wound areas. The results represent the means ± SEM of the number of positive cells per 
mm2, counted in ten different fields. Immunostaining for TNF-α (A), IL-8 (B), IL-10 (C) and CCR1 (D) in wound areas are shown. * indicates the 
difference (p < 0.05) relative to control.  The animals were treated with glycerol only; 10% L-arginine;  or with 40% L-arginine. All animals (n=5) were 
treated topically with L-arginine or vehicle (glycerol) 7 days before and 5 days after the laparotomy. Results are representative of two independent 
experiments. Statistical analysis were performed using one-way ANOVA followed by Bonferroni’s multiple comparison test. 
Effect of topical administration of L-arginine on the 
wound healing of immunosuppressed or diabetic 
mice 
Pathologic conditions, as diabetes and 
immunosuppression, were induced in mice and they were submitted 
to same experimental design described before in order to evaluate 
the influence of L-arginine in wound healing processes. Diabetic 
and immunosuppressed mice were topically treated with glycerol 
only (GD1, diabetic; GI1, immunosuppressed), or with L-arginine 
at concentrations of 10% (GD2, diabetic; GI1, immunosuppressed) 
or 15% (GD3, diabetic; GI3, immunosuppressed).
Diabetic animals topically treated with 10% or 15% 
of L-arginine, respectivelyGD2 and GD3, showed significant 
enhanced healing on the 5th day after the laparotomy, when 
compared with control, GD1 (Figure 7D, E and F) that showed 
polymorphonuclear cells infiltration, loose connective tissue and 
discreet neovascularization. On the other hand, in the groups treated 
with 10 or 15% of L-arginine, there were observed a small amount 
of mononuclear cells, well-structured conjunctive tissue, newly 
formed vessels and glands. Experimental immunosuppression 
induced on animals was confirmed by the decreasement in 
their leucocytes counting, which was significatively different 
after hydrocortisone administration (data not showed). Just like 
as healthy and diabetic animals, the immunosuppressed mice 
topically treated with L-arginine showed a different hystological 
pattern of wound process when compared with control group 
(Figure 7 D-F). L-arginine topical administration promoted 
changes in tissue morphology, like as the presence of granulation 
tissue and on collagen deposition aspects.  It was possible to 
observe a more heterogeneous morphologic pattern, with a 
remarkable inflammatory process in groups of animals treated 
with 10% of L-arginine (Figure 7E). Groups treated with 15% of 
L-arginine showed a homogeneous morphologic pattern, with a 
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mild inflammatory process showing isolated polymorphonuclear 
cells (Figure 7F). Tissues obtained from groups of diabetic 
and immunosuppressed animals treated with 10% or 15% of 
L-arginine, when stained with Masson trichrome method, showed 
a relative increase of collagen deposition (data not shown).
FIGURE 7 - Photomicrography (x200) of HE-stained wound sections 
from immunosuppressed (A-C-E) and diabetic (B-D-F) animals treated 
topically with different concentrations of L-arginine 7 days before and 
5 days after the laparotomy. All groups are analyzed in 5 DAL and the 
animals were treated topically with vehicle (glycerol) (A-B);  10% 
L-arginine(C-D)  or with 15% L-arginine.  
Comparison between topical and oral administra-
tion of L-arginine on the wound healing
Comparing both administration route, oral (GO2 
euthanized 5 days after laparotomy) and topical (GT3) 
corresponding to same dosis administration and observation 
conditions in health mice submitted to laparotomy, the results 
show that there were no significative difference in expression of 
iNOS or TGF-β between control groups, GT1 or GO1 (5 DAL). 
When groups  treated with 50 mg of L-arginine by 
day varying only the administration route, topical (GT3) or oral 
(GO2) 5DAL, were compared, the expression of iNOS was 
higher in animals topically treated, and there was an extremely 
significative (p < 0.0001) difference between the groups caused 
by the administration route. The same significative difference 
(p < 0.0001) was observed when the expression of TGF-β was 
analyzed comparing animals treated orally or topically with the 
same L-arginine dosis.
Discussion
Wound healing is a multi-step process that involves the 
coordinate action of matrix components, cytokines and growth 
factors16. Enzymes involved in L-arginine metabolism, including 
ARG and iNOS, are widely distributed in many different tissues. 
The present study demonstrates the beneficial effects 
of L-arginine on healing processes when orally or topically 
administered, either in healthy, immunosuppressed or diabetic 
mice. Arginine influenced expression of cytokines and growth 
factors involved in the healing process. The exact mechanism 
underlying the wound healing effect of arginine remain unclear12, 
but previous animal studies have suggested that arginine metabolites 
are envolved in the wound healing process12. Lately, Hol et al.11 
demonstrated that major surgeries has a higher decreasement on 
plasma levels of ornithine and NO than that observed in minor 
surgeries.  
Other previous work has established the importance 
of L-arginine in successful wound healing17, demonstrating that 
the impaired NO synthesis in the diabetic wound environment 
can be reversed, at least partially, by arginine supplementation. 
Their results suggested that L-arginine supplementation restores 
decreased healing in the acute wound model by normalizing 
the NO pathway without affecting arginase activity. Other 
experimental data suggested that the different arginine metabolic 
pathways are sequentially activated, and NO and ornithine levels 
are specifically elevated in wound fluids when compared to 
plasma18, and that different arginine metabolites could influence 
the early phases of healing induced by NO application19. Fujiwara 
et al.12, demonstrated that L-arginine supplementation stimulates 
fibroblast proliferation and also promote an anti-apoptotic effect 
in these cells, and the efects occur through activation of GPRC6A 
along with the activation of ERK1/2-CREB and PI3K/Akt 
pathway.
NO is a reactive nitrogen oxide specie that has 
been intensively studied for decades. NO also participates in 
inflammation by interfering with the activation of macrophages 
and T cells.  iNOS expression and NO production are associated 
with Th1 immune responses, but overexpression of  NO is 
associated with immunosuppression20.
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In the present work, oral or topical administration of 
L-arginine were evaluated in post surgical wound healing process. 
The results showed a decrease in the expression of iNOS in animals 
in which L-arginine was orally administered in comparision to the 
control animals. In parallel with histopathological analysis, the 
results suggested that the inflammatory process was attenuated 
five days after laparotomy, when tissues showed a decreased NO 
production, and it could had decreased the immunosuppressive 
mecanisms associated with high NO levels. However, as the 
tissues were first analysed on the fifth day after laparotomy, iNOS 
expression could have been high in the early stages of healing, 
since inflammation and tissue repair start quickly following lesion 
manifestation. It would be in accordance with the study realized 
by Finnen et al.19 that showed early healing after NO application. 
By the other hand, topical administration of L-arginine at 
40% was detrimental to tissue repair, as suggested by high levels 
of iNOS expression in tissues and histopathological analysis that 
indicated an acute inflammatory process. The intensity of the 
inflammatory process and cytokines envolved will determine if 
NO participates as a microbicidal or immunosuppressive agent21. 
Filipin et al.22 showed, in an experimental model of crush injury, 
that damage occurred with an intensive inflammatory reaction 
accompanied by increased oxidative damage, increased cytokine 
mRNA transcription and TGF-β growth factor expression in the 
gastrocnemius muscle. The treatment with a NO synthase inhibitor 
markedly decreased the histological and molecular damages and 
increased collagen formation. These data corroborate with results 
found in the present work.  
In this study, animals topically treated with L-arginine 
at 40% showed increased expression of IL-8 in the fifth day after 
laparotomy, probably due to the high intensity of inflammation 
process stablished, as well as the increased number of 
polymorphonuclear cells and NO production at the site of injury. 
In contrast, animals topically treated with L-arginine at 10% 
expressed significantly lower levels of IL-8 when compared with 
control animals, possibly as a result of their accelerated wound 
healing. IL-8 expression could have been higher at earlier stages 
of tissue repair, such as during the inflammatory phase, and could 
have enhanced angiogenesis (23), which would have contributed 
to faster healing. However, the time point chosen for tissue 
evaluation did not allowed the verification of this hypothesis.
Another important cytokine to the wound healing process 
is TGF-β, which activates genes associated with type I collagen 
production24 and promotes collagen production by fibroblasts25. 
TGF-β can promote collagen production by stimulating the 
arginase pathway as well as it is able to inhibit the iNOS pathway 
and result in an increase ornithine production by increasing the 
availability of arginine for arginase26. It was observed a significant 
increase in TGF-β levels in tissues of animals treated with 
L-arginine, either orally or topically, compared to those of control 
animals, and it was also observed that in topical treatment there 
was a higher expression of TGF-β than in the tissues of animals 
orally treated. It is tempting to speculate that the stimulation of 
macrophages with L-arginine leads to the production of TGF-β, 
which enhances collagen deposition by fibroblasts. L-arginine 
could also act indirectly by suppressing Th1 immune responses 
through the inhibition of Th1 cytokines, as indicated by the lower 
expression of iNOS in oral treatment6. 
The expression of IL-10 in the tissue of animals treated 
with L-arginine at 10% were similar to that found in the animals 
treated with glycerol only suggesting that, in this case, L-arginine 
did not affect the expression of IL-10. However, when animlas 
were topically treated with L-arginine dispersion at 40% of 
concentration, a significative change was observed, with a higher 
production of IL-10 in the tissue.  Eming et al.27 demonstrated 
that mice deficient for the anti-inflammatory cytokine interleukin 
10 (IL-10-/-) showed a accelerated wound healing, with a closed 
excisional wounds significantly earlier compared with IL-10-
competent control littermates. The authors discussed that this effect 
was attributable to a combination of accelerated epithelialization 
as well as increased wound contraction in the mutant animals. IL-
10-/- wound tissue contained more macrophages than wounds from 
control mice and formed a highly cellular granulation tissue27. 
Peranteau et al.28 investigated if  IL-10 overexpression could 
decrease inflammation and create an environment  conducive to 
scarless wound healing in adults. The authors concluded that this 
was an approach to be taken with caution, since wound healing 
process is composed by a serie of tightly regulated events whose 
attempt manipulation may result in unintended consequences. 
The results presented by the authors suggested that the IL-10 
overexpression acts providing an environment supportive of a 
regenerative healing process that is characteristic of scarless 
wound healing28. However, despite the accelerated wound 
closure showed by Eming et al.29 in IL-10 deficient mice, the 
mechanical strength of wounds in IL-10-deficient mice is reduced, 
indicating that IL-10 affects the quality of the repaired tissue27,28. 
In Peranteau et al.28 study, overexpression of IL-10 resulted in a 
decreased inflammatory infiltrate and a more organized collagen 
deposition. It is interesting to notice that when mice were 
topically treated with dispersion of L-arginine at 40%, there was 
an increase in the IL-10 expression and in this same group of 
animals it was observed an increased collagen deposition. Since 
Oral or topical administration of L-arginine changes the expression of TGF and iNOS and results in early wounds healing
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the administration of 40% L-arginine improved the expression of 
iNOS, the increased expression of IL-10 could be a compensation 
mechanism to control the inflammatory process, but it also could 
has acted as a mechanism to acquire a more organized collagen 
deposition, as occurred in the Peranteau et al.28 work. This, IL-
10 expression control it is another rote to be investigated in the 
relation of L-arginine administration and collagen deposition.
CCR1 gene encodes a member of the beta chemokine 
receptor family, which belongs to a family of G protein-coupled 
receptors. Among the ligands of this receptor are macrophage 
inflammatory protein 1 alpha, monocyte chemoattractant protein 
3, and myeloid progenitor inhibitory factor-1. Chemokines 
are critical for the recruitment of effector immune cells to the 
site of inflammation30. The levels of CCR1, which is expressed 
in lymphocytes, monocytes and eosinophils, decreased in 
animals topically treated with 10% L-arginine. This suggests an 
adicional evidence of the enhanced healing in the injured tissue. 
Histopathological analysis demonstrated a milder inflammatory 
process, suggesting that a higher expression of CCR1 could have 
occurred in an early phase of tissue repair, which is more dependent 
on lymphocytes, monocytes and eosinophils. Likewise occurred 
in the case of the IL-10 analysis, animals treated with L-arginine 
at 40% showed an increasement in the CCR1 expression, what 
can be occurring to compensate the more intense inflammation 
installed in the tissue.
Conclusions
Either topical or oral administration of L-arginine 
improves the wound healing process. For oral treatments, on fifth 
day after laparotomy, with daily L-arginine administration, TGF-β 
production was stimulated and NO levels were lower, leading to 
a reduced Th1 response and increased collagen deposition in the 
injured area. For topical treatments, the results showed a higher 
level of iNOS and TGF-β on the wound environment, suggesting 
an accelerated healing process. Overall, these results suggest that 
L-arginine, either oral or topically applied, may be an important 
factor in the recuperation of tissues following injury, and topically 
applied could be even more effective in accelerate the wound 
healing process.
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